|
Changes in HbA1c, BMI, serum lipids and creatinine, blood pressure and dose of antidiabetic drugs (n = 33) |
||||
| Baseline |
After 3 months |
After 6 months |
P |
|
|
|
||||
| HbA1c (%) |
10.9 ± 1.6 (9.0 – 14.4) |
7.8 ± 1.5 (5.9 – 11.3) |
7.4 ± 1.4 (5.5 – 12.7) |
< 0.001 |
| BMI |
23.8 ± 3.3 (18.0 – 33.8) |
23.5 ± 3.4 (16.8 – 32.8) |
23.5 ± 3.4 (17.1 – 32.7) |
0.057 |
| Serum LDL-cholesterol (mg/dl)* |
142 ± 50 (51 – 260) |
128 ± 34 (61 – 213) |
0.036 |
|
| Serum HDL-cholesterol (mg/dl)* |
52 ± 14 (30 – 77) |
59 ± 16 (34 – 94) |
0.008 |
|
| Serum triglyceride (mg/dl)* |
182 ± 189 (50 – 823) |
157 ± 178 (34 – 721) |
0.39 |
|
| Serum creatinine (mg/dl) |
0.68 ± 0.20 (0.38 – 1.20) |
0.71 ± 0.21 (0.44 – 1.25) |
0.21 |
|
| Systolic BP (mmHg) |
138 ± 17 (104 – 175) |
135 ± 14 (97 – 157) |
0.24 |
|
| Diastolic BP (mmHg) |
81 ± 11 (59 – 102) |
81 ± 11 (48 – 113) |
0.64 |
|
| Patients with antidiabetic drugs (n) |
||||
| Glibenclamide |
n = 6 (4.0 mg) |
n = 3 (1.7 mg) |
n = 1 (2.5 mg) |
|
| Glimepiride |
n = 1 (3.0 mg) |
n = 2 (0.75 mg) |
n = 0 (0 mg) |
|
| Tolbutamide |
n = 0 (0 mg) |
n = 0 (0 mg) |
n = 1 (500 mg) |
|
| Metformin |
n = 0 (0 mg) |
n = 2 (500 mg) |
n = 5 (600 mg) |
|
| Nateglinide |
n = 2 (135 mg) |
n = 2 (180 mg) |
n = 0 (0 mg) |
|
| Pioglitazone |
n = 0 (0 mg) |
n = 0 (0 mg) |
n = 2 (30 mg) |
|
| Miglitol |
n = 1 (150 mg) |
n = 3 (100 mg) |
n = 7 (125 mg) |
|
|
HbA1c: hemoglobin A1c; BMI: body mass index; BP: blood pressure. Values are means ± SD. The numbers in parenthesis in HbA1c, BMI, serum lipids, serum creatinine and blood pressure indicate ranges, and those in antidiabetic drugs show a mean daily dose. Two drop-out patients are included in the analysis. *: Four patients are excluded from serum lipids analysis because they received lipid-lowering drugs. | ||||
Haimoto et al. Nutrition & Metabolism 2009 6:21 doi:10.1186/1743-7075-6-21 |
||||